Prevalence and Mortality Rate of COVID-19 Disease in COPD Patients of Samutsakhon Hospital
Keywords:
chronic obstructive pulmonary disease (COPD), COVID-19Abstract
Objective: This was to study prevalence and mortality rate of COVID-19 and results of COVID-19 vaccination in COPD patients of Samutsakorn Hospital in 2021, and also to study risk factors COVID-19 in COPD patients.
Methods: A descriptive retrospective study was done by collecting data of COPD patients from database of COPD clinic’s computer program at Samutsakhon Hospital from 1 January to 31 December 2021. Data were analyzed using mean, SD, median, range, odds ratio, 95% CI, and p-value.
Result: There were 372 COPD patients in COPD clinic at Samutsakhon Hospital (2021) with median age of 69.5 ± 11.3 years, More males than females (85.8% vs 14.2%) . Most of the patients (39.2%) had body mass index of 20-25 whereas 32.5% of patients had body mass index less than 20. Only 7% of patients had current smoking history and 1.6% had alcohol drinking history.
The most underlying disease of COPD patients was hypertension (51.6%). In addition; 33.1% had dyslipidemia, 15.9 % had diabetes mellitus, equal 4.6 % had ischemic heart disease and chronic kidney disease, 3.2 % had old tuberculosis,and 1.1 % had cancer. Furthurmore, 96% of COPD patients had history of steroid used and 15.3 % had history of aspirin/clopidogrel/warfarin used.
Thirty of 372 COPD patients were found having COVID-19 infection (8.1%), of which1.6% were treated as OPD cases and 6.5% were admitted in the hospital. Three of 372 COPD patients died from COVID-19 infection (0.8%).
When analyzing data , no risk factors from the demographic data were found statistically associated with COVID-19 infection in this group of COPD patients.
About COVID-19 vaccination, 30.6% of COPD patients had no COVID-19 vaccine while 3.5% , 48.7%, 16.1%, and 1.1% of COPD patients had one, two, three and four doses of COVID-19 vaccine respectively. COPD patients who had no COVID-19 vaccine were the most found COVID-19 infected (4.0%) that had a statistically significant difference in COVID-19 infection among patients with COPD(p-value < .05). Among COPD patients who received three doses of the COVID-19 vaccine, there was anew a statistical difference in COVID-19 infection. (p-value < .001)
Conclusions: Thirty of 372 COPD patients were found having COVID-19 infection (8.1%), of which 1.6% were treated as OPD cases and 6.5% were admitted in the hospital.
Three of 372 COPD patients died from COVID-19 infection (0.8%).
References
Organization WH. Noncommunicable diseases (Available from: https://www.int/news-room/fact-sheets/detail/noncommunicable-diseases.
Organiztion WH.Key facts; Chronic obstructive pulmonary disease(COPD) 2021{18 June 2021}. Available from: http://who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease.
Organization WH. Who Coronavirus(COVID-19) Dashboard {18 June 2021}. Available from: https://covid19.who.int/.
Organiztion WH. Information note onCOVID-19 and NCDs 2020 {18 June 2021}. Available from: http://who.int/who-document-detail/covid-and-ncds.
Britto CJ BV, Lee S, Dela Cruz CS. Respiratory viral infections in Chronic Lung Diseases. Clin chest med. 2017;38(1):87-96.
Emami A, Javanmardi F, Pirbonyeh N, et al. Prevalence of underlying Diseases in Hospitalized Patients with COVID-19 : Systemic review and Metaanalysis. Arch Acad Emerg Med 2020;8(1):e35.
Gerayeli FV, Milne S1, Cheung C, et al. COPD and risk of poor outcomes in COVID-19: A systemic review and meta- analysis. EClinicalMedicine. 2021;33:100789.
Liu W, Tao ZW, Wang L, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Clin Med J 2020:133(9);1032–8.
Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995:332(20);1351–62.
Montón C, Ewig S, Torres A, et al. Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study. Eur Respir J. 1999;14(1):218–20.
So LK, Lau AC, Yam LY, et al. Development of a standard treatment protocol for severe acute respiratory syndrome. Lancet 2003;361:1615–7.
Ho JC, Ooi GC, Mok TY, et al. High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome. Am J Respir Crit Care Med 2003;168:1449–56.
Lee N, Hui D, Wu A, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003;348:1986–94.
Tsang KW, Ho PL, Ooi GC, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003;348:1977–85.
Qin YY, Zhou YH, Lu YQ, et al. Effectiveness of glucocorticoid therapy in patients with severe coronavirus disease 2019: protocol of a randomized controlled trial. Chin Med J (Engl) 2020;133:1080–6.
Zhou YH, Qin YY, Lu YQ, et al. Effectiveness of glucocorticoid therapy in patients with severe novel coronavirus pneumonia: protocol of a randomized controlled trial. Chin Med J (Engl) 2020;133(9):1080–6.
Lin Z, Phyu WH, Mon TZ, et al. The role of steroids in management of COVID-19 infection. Cureus 2021;13(8):e16841.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
ลิขสิทธิ์บทความเป็นของผู้เขียนบทความ แต่หากผลงานของท่านได้รับการพิจารณาตีพิมพ์ลงวารสารแพทย์เขต 4-5 จะคงไว้ซึ่งสิทธิ์ในการตีพิมพ์ครั้งแรกด้วยเหตุที่บทความจะปรากฎในวารสารที่เข้าถึงได้ จึงอนุญาตให้นำบทความในวารสารไปใช้ประโยชน์ได้ในเชิงวิชาการโดยจำเป็นต้องมีการอ้างอิงถึงชื่อวารสารอย่างถูกต้อง แต่ไม่อนุญาตให้นำไปใช้ในเชิงพาณิชย์
